戴纳基(DYN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DYN 戴纳基

未开盘 08-19 16:00:00 EDT

26.78

+0.78

+3.00%

盘后27.18

+0.40+1.50%

19:35 EDT

最高26.94	最低25.98	成交量195.21万
今开26.50	昨收26.00	日振幅3.69%
总市值49.97亿	流通市值49.81亿	总股本1.87亿
成交额5,184万	换手率1.05%	流通股本1.86亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DYN","market":"US","secType":"STK","nameCN":"戴纳基","latestPrice":26.78,"timestamp":1787169600000,"preClose":26,"halted":0,"volume":1952073,"hourTrading":{"tag":"盘后","latestPrice":27.1821,"preClose":26.78,"latestTime":"19:35 EDT","volume":33603,"amount":899953.0134,"timestamp":1787182549062,"change":0.4021,"changeRate":0.015015,"amplitude":0.015015},"delay":0,"changeRate":0.030000000000000044,"floatShares":186000000,"shares":186576800,"eps":-3.348564,"marketStatus":"未开盘","change":0.78,"latestTime":"08-19 16:00:00 EDT","open":26.5,"high":26.94,"low":25.98,"amount":51836658.235056,"amplitude":0.036923,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.348564,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787212800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1600315200000,"exchange":"NASDAQ","adjPreClose":26,"preHourTrading":{"tag":"盘前","latestPrice":26.56,"preClose":26,"latestTime":"09:29 EDT","volume":12485,"amount":327336.611635,"timestamp":1787146199999,"change":0.56,"changeRate":0.021538,"amplitude":0.134615},"postHourTrading":{"tag":"盘后","latestPrice":27.1821,"preClose":26.78,"latestTime":"19:35 EDT","volume":33603,"amount":899953.0134,"timestamp":1787182549062,"change":0.4021,"changeRate":0.015015,"amplitude":0.015015},"volumeRatio":1.136785,"impliedVol":0.7035,"impliedVolPercentile":0.7052},"requestUrl":"/m/hq/s/DYN","defaultTab":"news","newsList":[{"id":"1144151021","title":"Dyne Therapeutics宣布其针对面肩肱型肌营养不良症（FSHD）的候选药物Dyne-302获得美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1144151021","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144151021?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:31","pubTimestamp":1785238282,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics（戴纳基）今日正式宣布，美国食品药品监督管理局（FDA）已批准其针对面肩肱型肌营养不良症（Facioscapulohumeral Muscular Dystrophy, FSHD）的研究性新药（IND）申请。这意味着，该公司旗下的候选药物Dyne-302已获准进入人体临床试验阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DYN","BK4588","BK4505","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173314657","title":"戴纳基宣布完成扩大公开发行及承销商全额行使超额配股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1173314657","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173314657?lang=zh_cn&edition=full","pubTime":"2026-07-24 04:11","pubTimestamp":1784837519,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2026年7月23日——戴纳基，一家专注于为遗传性神经肌肉疾病患者改善功能的临床阶段公司，今日宣布其此前公布的扩大承销公开发行已圆满结束。此次发行共计21,045,000股普通股，公开发行价为每股20.50美元，其中包含承销商全额行使选择权后额外购入的2,745,000股。戴纳基从此次发行中获得的总收益约为4.314亿美元，该数字已扣除承销折扣、佣金以及公司需支付的发行费用。发行中的所有股份均由戴纳基出售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791710582.SGD","LU0053666078.USD","LU1720051108.HKD","MS","LU0795875169.SGD","LU1074936037.SGD","LU0098860793.USD","LU0557290698.USD","LU2271345857.HKD","BK4127","LU1548497426.USD","LU0225283273.USD","LU0528227936.USD","BK4588","LU1732800096.USD","LU0267386448.USD","LU2347655156.SGD","LU2487616109.SGD","BK4516","LU0106831901.USD","LU0158827781.USD","DYN","CNS","LU1244550577.SGD","LU0882574139.USD","LU1668664300.SGD","LU1732799900.SGD","LU1363072403.SGD","BK4504","LU2111349929.HKD","LU2089283258.USD","BK4534","LU0390134368.USD","LU2133065610.SGD","LU0912757837.SGD","KBWB","BK4135","IE00BZ1G4Q59.USD","BK4581","IE00BKVL7J92.USD","LU1064131342.USD","LU1989772840.SGD","LU2264538146.SGD","LU2028103732.USD","LU2089284900.SGD","LU1989772923.USD","LU1791710400.SGD","LU0795875086.SGD","LU0971096721.USD","LU0006306889.USD","BK4505","LU1162221912.USD","LU1244550494.USD","LU0234570918.USD","BK4139","LU0158827948.USD","LU0210528500.USD","LU0320765646.SGD","LU2023251221.USD","IAI","LU1244550221.USD","LU1720051017.SGD","LU2357305700.SGD","LU1988902786.USD","BK4585","LU0106261372.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101157039","title":"戴纳基宣布美国FDA受理Z-rostudirsen针对外显子51型杜氏肌营养不良症的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1101157039","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101157039?lang=zh_cn&edition=full","pubTime":"2026-07-20 19:31","pubTimestamp":1784547074,"startTime":"0","endTime":"0","summary":"戴纳基（Dyne Therapeutics）宣布，其针对外显子51型杜氏肌营养不良症（DMD）的在研药物Z-rostudirsen的生物制品许可申请（BLA）已获得美国食品药品监督管理局（FDA）的受理。这一进展标志着该疗法向潜在获批迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4588","DYN","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135479293","title":"戴纳基注册性扩展队列完成71名受试者入组，关键数据计划于2027年第一季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1135479293","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135479293?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:31","pubTimestamp":1780486284,"startTime":"0","endTime":"0","summary":"戴纳基（Dyne Therapeutics, Inc.）已成功完成其注册性扩展队列的受试者入组工作，共计招募了71名参与者。公司计划在2027年第一季度公布该项研究的核心顶线数据。\n这一进展标志着其临床开发项目迈出了重要一步，为后续的数据分析和潜在监管申报奠定了基础。研究团队将密切关注数据收集与分析的进程，以期按时达成既定的数据公布目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4505","BK4588","DYN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110959332","title":"戴纳基完成Z-Basivarsen治疗1型强直性肌营养不良症关键试验扩展队列患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1110959332","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110959332?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:30","pubTimestamp":1780486219,"startTime":"0","endTime":"0","summary":"戴纳基宣布，其针对1型强直性肌营养不良症的在研药物Z-Basivarsen，其关键性临床试验Achieve的注册扩展队列已完成患者入组工作。\n该进展标志着药物开发进程中的一个重要节点，为后续数据收集与分析奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4505","DYN","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195199683","title":"戴纳基寻求基于肌营养不良蛋白作为替代终点的加速批准提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1195199683","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195199683?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:33","pubTimestamp":1779795195,"startTime":"0","endTime":"0","summary":"戴纳基公司已提交申请，寻求基于肌营养不良蛋白作为替代终点，为其疗法获得加速批准。此项提交标志着公司在推进其治疗杜氏肌营养不良症候选药物方面迈出了关键一步。加速批准途径允许监管机构依据可能合理预测临床益处的替代终点来批准治疗严重疾病的药物，这可以显著缩短药物到达患者手中的时间。肌营养不良蛋白水平的恢复被广泛认为是杜氏肌营养不良症治疗中一个有潜力的替代标志物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","DYN","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142700635","title":"戴纳基因提交Z-Rostudirsen治疗外显子51型杜氏肌营养不良症的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1142700635","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142700635?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:32","pubTimestamp":1779795166,"startTime":"0","endTime":"0","summary":"戴纳基因公司宣布，已向美国食品药品监督管理局提交了其针对外显子51型杜氏肌营养不良症的在研疗法Z-Rostudirsen的生物制品许可申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","DYN","BK4505","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162385159","title":"戴纳基启动Z-Basivarsen治疗1型强直性肌营养不良症的三期Harmonia试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1162385159","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162385159?lang=zh_cn&edition=full","pubTime":"2026-03-09 06:02","pubTimestamp":1773007331,"startTime":"0","endTime":"0","summary":"戴纳基公司宣布，正式启动其候选药物Z-Basivarsen针对1型强直性肌营养不良症（DM1）的三期Harmonia临床试验。这一关键性研究旨在评估该疗法在DM1患者中的安全性与有效性，标志着公司在神经肌肉疾病治疗领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","DYN","BK4139","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132870393","title":"戴纳基公布24个月数据：Z-rostudirsen在DMD治疗中显著改善心肺功能","url":"https://stock-news.laohu8.com/highlight/detail?id=1132870393","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132870393?lang=zh_cn&edition=full","pubTime":"2026-03-09 06:01","pubTimestamp":1773007276,"startTime":"0","endTime":"0","summary":"最新公布的24个月临床数据显示，戴纳基（Dyne Therapeutics）研发的Z-rostudirsen在治疗杜氏肌营养不良症（DMD）过程中，对患者的心肺功能产生持续性改善。这一突破性进展为DMD患者提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","BK4139","DYN","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176762845","title":"戴纳基公布Z-Rostudirsen治疗杜氏肌营养不良症DELIVER试验新积极心肺结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1176762845","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176762845?lang=zh_cn&edition=full","pubTime":"2026-03-09 06:00","pubTimestamp":1773007216,"startTime":"0","endTime":"0","summary":"戴纳基公司近日宣布，其针对杜氏肌营养不良症研发的Z-Rostudirsen药物在DELIVER临床试验中取得了新的积极心肺功能数据。这项突破性进展标志着该疗法在改善患者心肺系统关键指标方面展现出显著潜力，为DMD治疗领域注入了新的希望。试验结果显示，Z-Rostudirsen在多项心肺功能评估参数上均表现出具有临床意义的改善。该公司表示将持续推进Z-Rostudirsen的研发进程，力争为DMD患者提供更有效的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4505","DYN","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518227151","title":"戴纳基盘中异动 早盘急速下跌5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518227151","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518227151?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:48","pubTimestamp":1741614488,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时48分，戴纳基股票出现异动，股价急速下跌5.24%。截至发稿，该股报11.75美元/股，成交量6.3116万股，换手率0.06%，振幅5.75%。机构评级方面，在所有13家参与评级的机构中，92%的券商给予买入建议，8%的券商给予持有建议，无券商给予卖出建议。戴纳基股票所在的生物技术行业中，整体涨幅为0.26%。戴纳基公司简介：Dyne Therapeutics Inc是一家专注于为基因驱动疾病患者提供治疗的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214809abf302ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214809abf302ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","BK4585","BK4505","DYN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517452626","title":"戴纳基2024财年实现净利润-3.17亿美元，同比减少34.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517452626","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517452626?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363243,"startTime":"0","endTime":"0","summary":"3月8日，戴纳基公布财报，公告显示公司2024财年净利润为-3.17亿美元，同比减少34.32%；其中营业收入为0.00美元，每股基本收益为-3.37美元。从资产负债表来看，戴纳基总负债61.40百万美元，其中短期债务4.85百万美元，资产负债比为0.12，流动比率为0.16。机构评级：截至2025年3月8日，当前有13家机构对戴纳基目标价做出预测，其中目标均价为48.15美元，其中最低目标价为18.00美元，最高目标价为66.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000127abed6604&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000127abed6604&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DYN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677819","title":"戴纳基盘中异动 早盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677819","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516677819?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:33","pubTimestamp":1741098836,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时33分，戴纳基股票出现异动，股价急速下跌5.03%。截至发稿，该股报11.70美元/股，成交量2.8713万股，换手率0.03%，振幅3.53%。机构评级方面，在所有12家参与评级的机构中，92%的券商给予买入建议，8%的券商给予持有建议，无券商给予卖出建议。戴纳基股票所在的生物技术行业中，整体跌幅为0.01%。戴纳基公司简介：Dyne Therapeutics Inc是一家专注于为基因驱动疾病患者提供治疗的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503042233569639453a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503042233569639453a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4588","BK4585","DYN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514332688","title":"戴纳基盘中异动 股价大跌5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514332688","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514332688?lang=zh_cn&edition=full","pubTime":"2025-02-28 04:14","pubTimestamp":1740687278,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日04时14分，戴纳基股票出现异动，股价大幅跳水5.15%。截至发稿，该股报13.08美元/股，成交量119.587万股，换手率1.18%，振幅7.83%。机构评级方面，在所有11家参与评级的机构中，91%的券商给予买入建议，9%的券商给予持有建议，无券商给予卖出建议。戴纳基股票所在的生物技术行业中，整体跌幅为0.32%。戴纳基公司简介：Dyne Therapeutics Inc是一家专注于为基因驱动疾病患者提供治疗的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228041438a256c675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228041438a256c675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4505","BK4139","DYN","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167334766","title":"Dyne Therapeutics 2024年第四季度每股收益 $(0.88)，优于预期$(0.99)","url":"https://stock-news.laohu8.com/highlight/detail?id=1167334766","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167334766?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:44","pubTimestamp":1740660293,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics  报告称季度每股亏损为$，比分析师一致预期的$高出11.11%。与去年同期每股亏损$相比，这是一个19.27%的改善。以上内容来自Benzinga Earnings专栏，原文如下：Dyne $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 11.11 percent. This is a 19.27 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","DYN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510338174","title":"戴纳基盘中异动 股价大跌5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510338174","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510338174?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:59","pubTimestamp":1739285988,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时59分，戴纳基股票出现波动，股价大幅跳水5.32%。截至发稿，该股报13.71美元/股，成交量7.4737万股，换手率0.07%，振幅3.59%。戴纳基股票所在的生物技术行业中，整体跌幅为1.29%。戴纳基公司简介：Dyne Therapeutics Inc是一家专注于为基因驱动疾病患者提供治疗的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112259489881c28a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112259489881c28a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4505","BK4139","DYN","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510898560","title":"戴纳基盘中异动 大幅下跌5.07%报14.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510898560","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510898560?lang=zh_cn&edition=full","pubTime":"2025-02-11 01:15","pubTimestamp":1739207744,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日01时15分，戴纳基股票出现波动，股价大幅下挫5.07%。截至发稿，该股报14.59美元/股，成交量21.8308万股，换手率0.21%，振幅5.47%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-97.13百万美元，每股收益-0.96美元，毛利-400000.00美元，市盈率-4.10倍。戴纳基股票所在的生物技术行业中，整体跌幅为0.22%。戴纳基公司简介：Dyne Therapeutics Inc是一家专注于为基因驱动疾病患者提供治疗的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211011544961e1fd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211011544961e1fd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4585","DYN","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509082132","title":"戴纳基盘中异动 快速拉升5.17%报16.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509082132","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509082132?lang=zh_cn&edition=full","pubTime":"2025-02-06 23:46","pubTimestamp":1738856793,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日23时46分，戴纳基股票出现波动，股价快速拉升5.17%。截至发稿，该股报16.49美元/股，成交量76.7181万股，换手率0.75%，振幅6.86%。戴纳基股票所在的生物技术行业中，整体涨幅为0.05%。其相关个股中，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc较为活跃，换手率分别为5558.48%、1369.62%、135.60%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Azitra Inc、Transcode Therapeutics, Inc.，振幅分别为103.10%、42.43%、39.93%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206234633987c9b18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206234633987c9b18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DYN","BK4585","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509123145","title":"戴纳基盘中异动 股价大涨5.07%报15.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509123145","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509123145?lang=zh_cn&edition=full","pubTime":"2025-02-06 01:23","pubTimestamp":1738776229,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日01时23分，戴纳基股票出现波动，股价急速上涨5.07%。截至发稿，该股报15.54美元/股，成交量38.5259万股，换手率0.38%，振幅4.90%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-97.13百万美元，每股收益-0.96美元，毛利-400000.00美元，市盈率-4.36倍。戴纳基股票所在的生物技术行业中，整体涨幅为2.07%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206012349abc3a24a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206012349abc3a24a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4505","DYN","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dyne-tx.com","stockEarnings":[{"period":"1week","weight":0.0233},{"period":"1month","weight":0.142},{"period":"3month","weight":0.5417},{"period":"6month","weight":0.7997},{"period":"1year","weight":1.1861},{"period":"ytd","weight":0.3691}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.1155},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Dyne Therapeutics, Inc.于2017年12月1日根据特拉华州法律注册成立。该公司正在建立一家领先的肌肉疾病公司，致力于开发针对遗传驱动疾病患者的创新性改变生命的疗法。该公司正在利用其专有的FORCE平台来克服当前肌肉组织输送的局限性，并发展用于肌肉疾病的现代寡核苷酸疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.011425},{"month":2,"riseRate":0.333333,"avgChangeRate":0.013319},{"month":3,"riseRate":0.5,"avgChangeRate":-0.02588},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.003166},{"month":5,"riseRate":0.666667,"avgChangeRate":0.03449},{"month":6,"riseRate":0.666667,"avgChangeRate":0.0741},{"month":7,"riseRate":0.833333,"avgChangeRate":0.142125},{"month":8,"riseRate":0.5,"avgChangeRate":0.052382},{"month":9,"riseRate":0.2,"avgChangeRate":-0.048359},{"month":10,"riseRate":0.333333,"avgChangeRate":0.031774},{"month":11,"riseRate":0.5,"avgChangeRate":0.097108},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.044634}],"exchange":"NASDAQ","name":"戴纳基","nameEN":"Dyne Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"戴纳基(DYN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供戴纳基(DYN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"戴纳基,DYN,戴纳基股票,戴纳基股票老虎,戴纳基股票老虎国际,戴纳基行情,戴纳基股票行情,戴纳基股价,戴纳基股市,戴纳基股票价格,戴纳基股票交易,戴纳基股票购买,戴纳基股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"戴纳基(DYN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供戴纳基(DYN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}